Chrystal Louis, M.D., M.P.H., is our Chief Medical Officer. Chrystal has two decades of experience across academia and industry where she built and managed high-performing clinical and medical affairs teams and worked on multiple regulatory approvals, new product launches, and strategies for label expansion. Prior to joining TScan, Dr. Louis was the SVP of hematology clinical development at Zentalis Pharmaceuticals. Dr. Louis held roles of increasing responsibility within medical affairs at CRISPR Therapeutics, Bristol Myers Squibb Company (BMS), and Celgene (acquired by BMS), as well as clinical development and project leadership at Merrimack Pharmaceuticals. Throughout the course of her career, she has been responsible for the design and oversight of clinical programs, medical strategy, and launch activities of novel therapeutic agents that have spanned small molecules to cell and gene therapies. Prior to joining industry, Dr. Louis was an Assistant Professor at Texas Children’s Cancer Center and Hematology Service, Baylor College of Medicine, where she worked on the early development of CAR-T cell therapy products for solid tumor malignancies. Dr. Louis received her M.D. from Tulane University School of Medicine, her Masters Degree in Public Health from Tulane University School of Public Health and Tropical Medicine, and her B.A. in Political Science and B.S. in Chemistry from Southwestern University at Georgetown, TX.

When not at TScan, Chrystal enjoys traveling and spending time with her family and friends.